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Supplementary Figure 1. Purification of Pdr5. a Size-exclusion chromatogram of Pdr5 
solubilised in trans-PCC-α-M, as described in Materials and Methods section. Pdr5 elution is 
marked by an asterisk. b Coomassie-blue stained SDS-PAGE of purified Pdr5 (single repeat). 
c Western blot of the SDS-PAGE using a polyclonal Pdr5 antibody (single repeat). Molecular 
weight standards are given to the left of the SDS-PAGE and the Western blot. Source data 












Supplementary Figure 2. Reconstitution of Pdr5 into peptidics. a Size-exclusion 
chromatogram of Pdr5 reconstituted into peptidisc, as described in Materials and Methods 
section. The peak of reconstituted Pdr5 is indicated by an arrow. b Pdr5 specific ATPase 
activity of reconstituted Pdr5. Error bars present mean ± standard error of three independent 
experiments. c Coomassie-blue stained SDS-PAGE of Pdr5 samples of known concentration 
and elution fractions of the reconstitution experiment (single repeat). d Calibration line of the 
samples of Pdr5 of known concentration (black circles) and the three elution fractions of the 
reconstitution experiment (green squares, E11 to E13 from left to right). The equation of the 






Supplementary Figure 3. Cryo-EM imaging of Pdr5. a Cryo-EM micrograph (selected from 
a set of 3,415) of Pdr5/peptidisc particles in vitrified ice (ADP-Pdr5 sample). Scale bar is 300 
Å. b Averaged images of the particles, obtained in reference-free 2D classification. c Angular 
distribution of particle orientations in Pdr5 samples prepared with and without the addition 
of CHAPSO. d Cryo-EM map of apo-Pdr5, coloured by local resolution (see key). e Gold-
standard FSC curves showing the correlation between the half-datasets in the unmasked 
(black line) and masked (red line) maps. The overall resolution was judged using the FSC0.143 
threshold (dashed line). f–k Cryo-EM maps and FSC curves for the other Pdr5 reconstruction, 
analogous to d–e. See also: Supplementary Table 1. 
Abbreviations: FSC, Fourier-shell correlation. 
 
 
Supplementary Figure 4. Cryo-EM processing workflow for Pdr5 datasets. The diagram 
depicts schematically the steps in the computational analysis of the cryo-EM datasets that 
were collected in this study and used to reconstruct the four Pdr5 maps: apo-Pdr5, ADP-
Pdr5, R6G-Pdr5 and AOV-Pdr5. Software packages, programs and individual procedures are 
listed, together with micrograph and particle numbers. Additional information is found in 




Supplementary Figure 5. Annotated amino-acid sequence of Pdr5. Indicated are 
conserved features of the nucleotide binding sites (black boxes) and positions of α-helices 
(coloured boxes). The domains of Pdr5 are indicated, and the helices are coloured according 
to the scheme used elsewhere in the paper. Grey residues indicate parts of the ADP-Pdr5 
model that could not be resolved in the cryo-EM map.  
Abbreviations: DL, D-loop; ECD, extracellular domain; H, H-loop; LD, linker domain; NBD, 
nucleotide-binding domain; Q, Q-loop; SM, signature motif; TH, transmembrane helix; TMD, 




Supplementary Figure 6. Domain topology of Pdr5. A schematic representation of domain 
architecture of Pdr5 showing the arrangement of its secondary structural elements. Cylinders 
and arrows represent alpha-helices and beta-sheets. The elements on the diagram are not 
shown to scale, but their relative positioning in the two halves of the protein reflects the 
evolutionary relation of the transporter domains through a gene-duplication event. The colour 
scheme for domains is similar to the one used elsewhere in text. The dashed lines represent 
structure fragments that could not be resolved in the ADP-Pdr5 map (cf. Supplementary 
Figure 5). The circled letters “S” denote the position of disulphide bridges. According to the 
alternative nomenclature proposed for the PDR family1, ECD1 and ECD2 are respectively EC3 
and EC6. 
Abbreviations: ECD, extracellular domain; LD, linker domain; NBD, nucleotide-binding 
domain; TMD, transmembrane domain. 
 
 
Supplementary Figure 7. Liquid drug assay for Pdr5 linker domain mutants. Yeast cells 
expressing Pdr5 (blue) or mutants in the linker domain (LD) were incubated for 48 hours at 30 
°C with four different drugs at indicated concentrations. Subsequently, optical density at 600 
nm (OD600) was measured. Data were analysed using a log (inhibitor) vs response function 
implemented in Prism 9 (GraphPad Inc.). Experimental details of the assay are provided in 
the Methods section. The drugs investigated were a R6G, b fluconazole, c ketoconazole, and 




Supplementary Figure 8. ATPase activity of Pdr5 linker domain mutants in plasma 
membrane vesicles. a Coomassie-stained SDS-PAGE (single repeat) of plasma membrane 
vesicles containing wild-type Pdr5 and mutants in the linker domain (LD). The signals of Pdr5 
and Pma1 (normalisation standard) are indicated with arrows. Densiometric analysis (Fiji) 
indicated differences in expression levels below 10%. The same result was obtained when 
taking the signal intensity of Pma1 into account. Therefore, no expression level correction 
was applied. b ATPase activity of Pdr5 reconstituted in plasma membrane vesicles. Shown 
are the kinetic curves for the ATP hydrolysis by wild-type protein and linker domain mutants. 
The experiment was performed using n=3 biologically independent samples examined over 
3 independent experiments. Error bars in figure represent mean ± standard error.  See also: 







Supplementary Figure 9. Glycosylation of Pdr5. Figure shows the side view of the Pdr5 
and, in inset, a putative glycosylation site on the extracellular domain of Pdr5. The two 
transparent surface representations of the apical portion of Pdr5 are from the same ADP-
Pdr5 cryo-EM map, contoured at two different levels. The inner surface shows the Coulomb 
potential map immediately surrounding the protein; the outer is a noisier and Gaussian-
filtered (2σ) version of the map, showing the protrusion around the asparagine residue 
(labelled), previously suggested to be glycosylated. 
Abbreviations: ECD, extracellular domain; TMD, transmembrane domain. 
 
 
Supplementary Figure 10. Details of protein-ligand interactions in Pdr5. Schematic 
representation of the network of molecular interactions between the nucleotides and the 
protein in the canonical and inactive nucleotide-binding sites of the a inward-facing ADP-
Pdr5 and b the outward-facing AOV-Pdr5. The interactions between the transport substrate 
rhodamine 6G and the residues in the c substrate entry channel in the inward-facing R6G-
Pdr5 are similarly depicted. Also shown is the superposition of cartoon models of R6G-Pdr5 
and human multi-drug transporter ABCG2 (pink, PDB-ID: 6VXI) in complex with d the 
chemotherapy drug mitoxantrone. Interaction diagrams were prepared with LigPlot+2. Atoms 
are depicted as coloured balls (C, black; N, blue; O, red; P; purple; S, yellow; Mg, V, green), 
ligand covalent bonds are purple and protein bonds are brown. Dashed green lines represent 
hydrogen bonds or other electrostatic interactions, with inter-atom distances indicated in Å. 
The radiating arc symbol represents amino-acid residues involved in hydrophobic contacts. 






Supplementary Figure 11. Analysis of potential entry sites in the inward-facing 
conformation of Pdr5. a Cartoon representation of the inward-facing state and the present 
tunnels (magenta) as determined by CAVER-3.03. b Surface representation of Pdr5. This 
analysis demonstrates that Pdr5 has only one membrane entry site between helices TH1b 
and TH11a, while the corresponding entrance on the opposite side is closed by TH4 and 




Supplementary Figure 12. Structural differences between Pdr5 models. Shown here are 
structural overlays of Pdr5 models in cartoon representation: ) between apo-Pdr5 and ADP-
Pdr5, with the inset showing details of the NBD2 domain around the catalytic NBS; b AOV-
Pdr5 and ADP-Pdr5 (or outward-facing and inward-facing conformations); c between R6G-
Pdr5 and ADP-Pdr5 in the region surrounding the rhodamine 6G transport substrate. In 
panels a–c, ADP-Pdr5 structure is used as a reference and is coloured grey. Other models 
follow the domain colouring scheme used elsewhere in the paper. d The diagram depicts the 
difference between the conformation of NBD1 domain of Pdr5 in outward- and inward-facing 
models (ADP-Pdr5 and AOV-Pdr5). In ADP-Pdr5, the N-terminal helices H1 and H2 are clearly 
resolved in the cryo-EM map, unlike helix H15, which did not adopt a discrete conformation. 
In AOV-Pdr5, H15 moves towards transmembrane helix TH1a, displacing H2 and H1, the 
latter of which is no longer visible in the map. Dashed lines denote the approximate position 
of unresolved helices, and arrows are an indication of movement. 
Abbreviations: ECD, extracellular domain; NBD, nucleotide-binding domain; R6G, rhodamine 





Supplementary Figure 13. Leucine gate of human ABCG2 and the corresponding region 
of Pdr5. Human ABCG2 (grey, PDB-ID: 6HCO [http://doi.org/10.2210/pdb6HCO/pdb]) and 
Pdr5 (coloured) were superimposed and the residues of ABCG2 forming the di-leucine gate 
(L554 and L555) are highlighted (ABCG is a homodimer). The corresponding residues of Pdr5 

































Supplementary Table 1. Cryo-EM data collection and refinement statistics 











EMDB ID  
 
EMD-13142 EMD-13143 EMD-13144 EMD-13145 
Data collection     
Microscope FEI Titan Krios FEI Titan Krios FEI Titan Krios FEI Titan Krios 
Voltage (kV) 300 300 300 300 
Detector K2 Summit K3 K3 K3 
















Electron fluency, per frame (e–
/Å2) 
1.452 0.96 0.97 0.98 
Electron fluency, total (e–/Å2) 58.1 47.21 47.73 48.13 
Defocus range (µm), step (µm) 
Exposure (s) 
Frames 
Number of micrographs 
 
















Reconstruction     




RELION-3.1 RELION-3.1 / 
cryoSPARC-3.0 
Final number of particle images 68,154 95,283 76,419 55,155 
Est. translational accuracy (pix) 
Est. rotational accuracy (°) 













Map-sharpening B factor (Å2) 
 
–102.9 –47.4 –55.0 –83.3 
Model composition     






1 × ATP  
1 × ADP 
1,353 
1 × ATP  
1 × ADP 
1 × R6G 
1,350 
1 × ATP  
1 × AOV 
1 × MG 
 
Refinement 
    
Software Phenix-1.18.2 Phenix-1.18.2 Phenix-1.18.2 Phenix-1.18.2 
Correlation coefficient, masked 0.80 0.81 0.82 0.79 
Correlation coefficient, box 0.67 0.60 0.66 0.52 
Model resolution, FSC0.5 (Å) 
 
Validation (proteins) 
3.7 3.0 3.3 3.6 
MolProbity score 1.71 1.62 1.67 1.91 
Clash score, all atoms 6.14 7.14 7.16 9.39 
EMRinger score 
 
Ramachandran plot statistics 
3.09 – – – 
Favoured, overall (%) 94.63 96.5 95.97 93.82 
Allowed, overall (%) 5.37 3.5 4.03 6.81 
Outlier, overall (%) 0.06 0 0 0 
 
R.m.s. deviations 
    
Bond length (Å) 0.006 0.073 0.006 0.006 





Supplementary Table 2. Structural alignment of Pdr5 and related proteins. 
 
Transporter PDB-ID R.m.s.d. vs. Pdr5 IF* [Å]  R.m.s.d. vs. Pdr5 OF** [Å] 
TarGH 6jbh 14 (359) 13.9 (358) 
Wmz-Wzt / ATP 6m96 9.2 (343) 8.8 (338) 
Wmz-Wzt / ATP-Mg2+ 7k2t 13.4 (727) 10.5 (667) 
ABCA1 5xjy 33.3 (762) 36.3 (808) 
ABGG2 OF** 6hbu 5.1 (1006) 2.8 (881) 
ABCG2 IF* 6hco 3.9 (929) 6.8 (988) 
ABCG5/G8 5do7 4.3 (753) 6.6 (821) 
 
Note: R.m.s.d. calculation considered only backbone atoms and was carried out in PyMOL 
(Schrödinger LLC). Numbers in parentheses indicate residue range of alignment. *: inward-
facing; **: outward-facing. 
 
 
Supplementary Table 3. Summary of the statistical analysis of the liquid drug assays. 
 
Mutation Drug 
R6G FC KC CH 
Q801A 0.9976 (ns) 0.9817 (ns) 0.7321 (ns) <0.0001 (****) 
Q801V 0.9924 (ns) <0.0001 (****) 0.9212 (ns) <0.0001 (****) 
K802A 0.9226 (ns) <0.0001 (****) 0.1629 (ns) 0.0002 (***) 
K802E 0.9968 (ns) 0.0032 (**) 0.0015 (**) <0.0001 (****) 
G803A 0.9998 (ns) 0.0468 (*) 0.8752 (ns) 0.9998 (ns) 
G803V 0.2768 (ns) 0.9927 (ns) 0.9931 (ns) 0.4863 (ns) 
E804A 0.0036 (**) <0.0001 (****) 0.9974 (ns) 0.9112 (ns) 
I805S 0.9998 (ns) 0.9994 (ns) 0.0002 (***) <0.0001 (****) 
 
Note: Analysis was carried out using a one-way ANOVA test in Prism 9 (GraphPad Inc.). ****: 
p < 0.0001, ***: p < 0.0005, **: p < 0.005, *: p < 0.5, not significant (ns): p > 0.5. See also: 
Supplementary Figure 7. Abbreviations: R6G, rhodamine 6G; FC, fluconazole; KC, 
ketoconazole; CH, cycloheximide. 
 
 
Supplementary Table 4. Summary of the kinetic parameters of the ATPase activity of wild-
type Pdr5 and the mutants of the linker domain.  
 
 
Note: Statistical analysis was caried out using a one-way ANOVA test (Prism 9, GraphPad 
Inc.) and revealed no significant differences (ns) in KM, but highly significant differences for 





Mutation KM [mM] Vmax [µmol min-1 mg-1] Difference with wild type 
KM Vmax 
Wild type 1.7 ± 0.2 3.2 ± 0.1 – – 
Q801A 1.1 ± 0.4 1.7 ± 0.2 0.5913 (ns) <0.0001 (****) 
Q801V 2.0 ± 0.3 1.6 ± 0.1 0.98 (ns) <0.0001 (****) 
K802A 0.9 ± 0.2 0.8 ± 0.1 0.2786 (ns) <0.0001 (****) 
K802E 1.3 ± 0.2 1.7 ± 0.1 0.9078 (ns) <0.0001 (****) 
G803A 0.7 ± 0.1 1.1 ± 0.1 0.1016 (ns) <0.0001 (****) 
G803V 1.6 ± 0.4 1.2 ± 0.1 0.9997 (ns) <0.0001 (****) 
E804A 2.3 ± 0.4 1.2 ± 0.1 0.5913 (ns) <0.0001 (****) 
I805S 1.7 ± 0.3 3.2 ± 0.2 >0.9999 (ns) >0.9999 (ns) 
Supplementary Table 5. Selected mutations of Pdr5 with functional impact and possible 
structural explanation of the observed functional modulation of Pdr5. 
 
Mutation Location Modulation of 
Pdr5 function 
Reference Explanation based on the structures 
E244G Q-loop of NBD1 Increased drug 
sensitivity 
4 Interaction with D-loop of NBD1 
T257I H6 Alters drug 
specificity 
Uniprot P33302 Not evident 
G302D Loop preceding 




Uniprot P33302 Stabilizes the conformation of the C-loop of NBD1 
S558Y TH2 Impaired 
transport 
activity 
5 Interacts with the linker TH11a-TH11b 
S648F TH4 Alters drug 
specificity 
Uniprot P33302 Forms a helical bundle with TH5c and TH6 




Uniprot P33302 ATP binding / hydrolysis 




Uniprot P33302 ATP binding / hydrolysis 
Q951G Q-loop of NBD2 Increased drug 
sensitivity 
4 ATP binding / hydrolysis 
G1009C Loop preceding 




Uniprot P33302 Interaction with LD1 (QKGEIL) 
G1040D D-loop of NBD2 Alters drug 
specificity 
Uniprot P33302 Impaired NBD-NBD communication 
D1042N D-loop of NBD2 Alters drug 
specificity 
6 Impaired NBD-NBD communication 
S1048V H23 Alters drug 
specificity 
Uniprot P33302 Not evident 
Y1311S TH9b Alters drug 
specificity 
Uniprot P33302 Cluster of Y residues (1301, 1305, 1306, 1311) 
S1360F TH11a Alters drug 
specificity 
7 Part of the R6G binding site 
S1386A TH11a Creates bi-
directional 
transport 
8 On top of the R6G binding site 
T1393I TH11c Alters drug 
specificity 
Uniprot P33302 On top of the R6G binding site 
 
Note: The multiple suppressor mutants of Pdr5, which have been described in the literature 
(see, for example4,9), have been excluded due to potential additive effects that cannot be 
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